EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC 3.0

Methodological and Outcome Interpretation Concerns for the Food-Effect Study of Bersiporocin [Letter]

Danfeng Shen iD, Hongxing Xu

Drug Design, Development and Therapy · 2026-07 · Volume 20 · 1-3

DOI: 10.2147/dddt.s643052 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Drug Design, Development and Therapy, 2026-07. Verfasst von Danfeng Shen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Taicang Affiliated Hospital of Soochow University, Suzhou, 215400, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We read with great interest the article by Lee et al regarding the food effect study of bersiporocin. 1 Although the authors' work characterizing the effect of meal timing on pharmacokinetics (PK) and gastrointestinal (GI) tolerability is commendable, we argue that multiple critical methodological and interpretative flaws compromise the validity of their conclusions.These concerns have substantial regulatory and clinical implications that warrant careful reconsideration.First, the authors' conclusion that food "did not have a clinically significant effect on systemic exposure" is based exclusively on the observation that AUC last geometric mean ratios (GMRs) remained within the 80-125% bioequivalence range.However, this conclusion completely ignores the magnitude of C max reduction, a parameter that regulatory agencies universally recognize as co-primary with AUC in food effect assessments.2,3 Under the 30-minute postprandial condition (Treatment B), the C max GMR for bersiporocin was 0.5262 (90% CI: 0.4334-0.6388);under the 2-hour postprandial condition (Treatment C), it was 0.6744 (90% CI: 0.5540-0.8211).Both confidence intervals fall far outside the 80-125% acceptance range that defines "no food effect".2,3 As recently reviewed, even when AUC remains unchanged, a food-induced Cmax change of 30-50% is consistently considered clinically meaningful and often triggers explicit dosing recommendations.4 For a chronic disease like Idiopathic Pulmonary Fibrosis (IPF), where maintaining consistent therapeutic levels is essential, a 33-48% reduction in peak concentration cannot be dismissed as insignificant.Second, the authors' mechanistic explanation for the increased GI adverse events (AEs) in the 30-minute postprandial group is physiologically inconsistent with their own PK data.Specifically, they proposed that gastric contents and elevated intragastric pH can compromise the integrity of the enteric coating and induce premature drug release.To our knowledge, the claim that high-fat meals impair enteric coating integrity lacks direct evidence.The enteric coating is designed to resist dissolution at gastric pH and only dissolve after reaching the higher pH environment of the small intestine.5 If premature drug release occurs in the stomach, accelerated rather than delayed drug absorption would be expected.However, the research results show that the median T max increased from 3 h in the fasted state to 6 h in both fed conditions.This paradoxical pattern-earlier release but a later systemic peak-cannot be explained by the previously proposed mechanism.Instead, it can be better accounted for by the fact that prolonged gastric residence under fed conditions is more likely to delay drug release into the intestine.6 Therefore, the increased incidence of GI AEs in the 30-minute postprandial group may be due to other underlying mechanisms.Third, the authors' attempt to distinguish peripheral (local GI irritation) from central (systemic exposure) mechanisms of nausea and vomiting is undermined by a circular reasoning flaw.The authors note that "systemic exposure did not differ between participants with and without vomiting" and use this observation to argue against a central mechanism.However, if vomiting occurred shortly after dosing (before complete drug absorption), lower systemic exposure would actually be expected in vomiters compared with non-vomiters.The fact that AUC values were comparable between groups does not exclude a systemic Therapy 2026:20 643052 1 Drug Design, Development and

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, Taicang Affiliated Hospital of Soochow University, Suzhou, 215400, People's Republic of China.

ORCID-Profile: Danfeng Shen

Zitieren

APA

Shen, D., & Xu, H. (2026). Methodological and Outcome Interpretation Concerns for the Food-Effect Study of Bersiporocin [Letter]. Drug Design, Development and Therapy, Volume 20, 1-3. https://doi.org/10.2147/dddt.s643052

Vancouver

Shen D, Xu H. Methodological and Outcome Interpretation Concerns for the Food-Effect Study of Bersiporocin [Letter]. Drug Design, Development and Therapy. 2026;Volume 20:1-3. doi:10.2147/dddt.s643052

BibTeX
@article{Shen2026,
  author = {Shen, Danfeng and Xu, Hongxing},
  title = {Methodological and Outcome Interpretation Concerns for the Food-Effect Study of Bersiporocin [Letter]},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--3},
  doi = {10.2147/dddt.s643052}
}
Kostenlos starten →